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I.  INTRODUCTION 
Infectious diseases remain a major cause of human deaths worldwide. Against many 
traditional pathogens significant progress has been made by development of sensitive 
diagnostic tests, antibiotic and antiviral drugs, and efficient vaccines; whereas 
emerging and reemerging zoonotic infectious diseases represent still a major 
challenge for public health prevention strategies. 
Modern vaccines against emerging pathogens have to fulfill different requirements: 
rapid and flexible generation of safe and efficient vaccines with technologies that can 
facilitate accelerated regulatory review. Different strategies like inactivated vaccines, 
live-attenuated vaccines, subunit or DNA vaccines, and viral vector vaccines are used 
to meet these needs. Especially, poxvirus vector vaccines are thought to be among 
the best experimental means to induce cellular immunity and humoral responses. The 
Modified Vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus 
originating from growth selection on chicken embryo fibroblasts, is widely used in 
experimental vaccine development targeting infectious pathogens as well as cancer. 
Technologies for genetic engineering, large scale production, and quality control have 
been established and match today’s requirements.  
In this work the MVA vector system was used to generate a candidate vaccine against 
a newly emerging pathogen, the Middle East respiratory syndrome coronavirus 
(MERS-CoV). This novel coronavirus is causing a severe respiratory disease and 
deaths in humans and was first described in 2012. The virus is suspected to persist in 
animal reservoirs and cause zoonotic infections in humans.  
MVA expressing the full-length spike protein of MERS-CoV was constructed and 
characterized by genetic engineering and molecular analysis. Mice vaccinated with the 
recombinant MVA produced high levels of serum antibodies that neutralized MERS-
CoV in tissue culture infections. 
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II.  LITERATURE 
1 Emerging infectious diseases 
Emerging infectious diseases can be divided into two categories. Newly emerging 
infectious diseases are recognized in the human host for the first time, and reemerging 
infectious diseases are diseases that historically have infected humans but continue to 
reappear either in new locations or in resistant or new forms or reappear after 
apparent control or elimination (Fauci and Morens, 2012). In the past two decades, 
humans have faced many new viral infectious agents in emerging infection (Table 1). 
Emerging disease 
Year 
identified 
Estimated global impact 
Cases Death 
Human Immunodeficiency Virus / Acquired 
Immune Deficiency Syndrome (HIV/AIDS) 
1981 35.3 million 36 million 
H5N1 Influenza (“bird flu”) 1997 637 378 
Severe Acute Respiratory Syndrome (SARS) 2003 8096 774 
H1N1 (2009) Influenza (“swine flu”) 2009 unknown >280000 
Middle East Respiratory Syndrome (MERS) 2012 153 64 
H7N9 Influenza (“bird flu”) 2013 137 45 
Table 1 Selected emerging diseases                              
(from http://kff.org/global-health-policy/fact-sheet/the-u-s-government-global-emerging-
infectious-disease-preparedness-and-response; modified) 
 
For example the severe acute respiratory syndrome (SARS) was first reported in 
Guangdong, China in 2002, but within one year the disease quickly spread worldwide 
(Figure 1). Over all the World Health Organization (WHO) reported more than 8000 
infected people and 774 deaths. The etiologic agent was the SARS coronavirus 
(SARS-CoV), a lineage B betacoronavirus, which jumped to humans from animal 
reservoirs, especially bats, Himalayan palm civets and raccoon dogs (Graham et al., 
2013; Guan et al., 2003; Shi and Hu, 2008). Virus spread in human populations 
happened firstly by person-to-person transmission in confined spaces, then within 
hospitals, and finally by human movement between international air hubs (Hsueh and 
Yang, 2003).  
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Figure 1 Cases of severe acute respiratory syndrome (SARS) from November 
2002 to July 2003. SARS-related deaths indicated in parentheses.                                           
(from Morens et al., 2004, with permission) 
 
The SARS pandemic caused great economic losses, associated with disruptions of 
trade, travel, investment, interruption of product supply chains and behavior changes 
in consumers, rather than from medical costs or the loss of human life. The Asian 
Development Bank calculated a global economic loss of about 59 billion US$ (Baric, 
2008; Gupta et al., 2005) (Figure 2).  
 
Figure 2 Economic impact of SARS compared with other emerging diseases            
(from SARS and the New Economics of Biosecurity, 2003) 
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Besides the SARS-CoV infection there are many other examples for emerging 
zoonotic virus diseases. In 1998-1999 nipahvirus emerged from fruit bats in Malaysia 
and caused an epizootic in herds of intensively bred pigs which in turn served as the 
animal reservoir from which the virus was passed on to humans causing more than 
100 deaths (CHUA, 2000). Only two years later the same virus emerged in India and 
Bangladesh causing more than 200 deaths to date. Also here fruit bats are the animal 
reservoir and transmit the nipahvirus to humans through shedding and contaminating 
fruits and other food (for example palm sap) (Kulkarni et al., 2013; Luby et al., 2009; 
Luby et al., 2006). 
In 2009 the pandemic H1N1 influenza virus emerged also from pigs, after complex 
genetic reassortment of North American swine, Eurasian swine, North American avian, 
and human influenza virus strains (Garten et al., 2009; Smith et al., 2009). The H5N1 
influenza subtype first infected humans during an outbreak of avian influenza in Hong 
Kong in 1997. After re-emergence in 2003 and 2004, influenzavirus H5N1 has spread 
from Asia to Europe and Africa. Until today millions of infections in poultry, about 
seven hundred human cases, and more than 300 human deaths were the 
consequence (WHO). H7N9 bird flu is the newest atypical influenza virus infection that 
has just been reported since early 2013. The emerging of this new disease occurred in 
China and becomes the presently most closely observed virus concerning the threat of 
a new influenza A virus pandemic (Wiwanitkit, 2013).  
Also when these are only some of the latest examples, it is clear, that infectious 
diseases have been emerging and reemerging over a long period. There a numerous 
factors, including genetic, biological, social, political and economic factors, that 
contribute to emergence and reemergence of infectious diseases (Table 2). 
 
Microbial Agent Human Host Human environment 
Genetic adaptation and 
change 
Susceptibility to infection Climate and weather 
Polymicrobial diseases Demographics and behavior Changing ecosystems 
 International trade and travel Economic development and 
land use 
 Occupational exposures Poverty and social inequality 
  Lack of public health services 
  Animal populations 
Table 2 Factors involved in the emergence of infectious diseases                            
(from Morens et al., 2004, modified) 
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Infectious diseases will continue to emerge and reemerge. Therefore, fast 
developement of pathogen-specific diagnostic tests and treatment strategies as well 
as vaccine development are important countermeasures. 
2 Vaccines against emerging infectious diseases 
Vaccines are among the most cost-effective public health prevention strategies for 
combating infectious diseases. Marano et al. (2007) illustrated the importance of 
vaccines for emerging zoonotic infections. For example vaccination of animals can be 
an important tool for control of zoonotic disease (e.g. West Nile fever and avian 
influenza). But emerging and reemerging infectious pathogens are a major challenge 
to vaccine development. On one hand vaccine generation, testing and production 
must be rapid and flexible, to accommodate the abrupt appearance of the causing 
pathogen, on the other hand the technologies for vaccine generation and production 
must be consistent, highly standardized, and reproducible to facilitate accelerated 
regular review (Leblanc et al., 2012). 
Multiple strategies can be used to generate vaccines against emerging virus diseases, 
which include inactivated vaccines, live attenuated vaccines, subunit vaccines, DNA 
vaccines and vector vaccines. All types of vaccines have certain advantages and 
disadvantages. Graham et al. (2013) reviewed different strategies that were used to 
generate SARS-CoV-specific vaccines. Inactivated virus vaccines were prepared by 
use of chemicals or radiation. Thus, the virion structure is maintained, but the virus 
cannot infect, propagate or cause disease. The vaccines were used with or without 
adjuvant. In most studies high level of neutralizing antibodies was induced, but also 
adverse side effects like T helper 2-stimulation and interleukin-4-driven inflammatory 
pathology were observed (Bolles et al., 2011; Roper and Rehm, 2009; See et al., 
2006).  
Live-attenuated virus vaccines can elicit T cell- and B cell-dependent immune 
responses (Vignuzzi et al., 2008). For SARS-CoV mutants lacking the envelope 
protein or the exonuclease ExoN were replication attenuated and were able to protect 
mice in challenge experiments (Eckerle et al., 2010; Fett et al., 2013; Netland et al., 
2010). Nevertheless, recombination events with wild-type coronaviruses might cause 
reversion to virulence. 
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For subunit vaccines the antigenic components are generated in vitro. The spike and 
the nucleocapsid proteins served as target antigens for SARS-CoV vaccines (Bisht et 
al., 2005; Gupta et al., 2006; Liu et al., 2006). Subunit vaccines cannot cause viral 
disease, but can induce B cell- and T cell-dependent immune responses. Bisht et al. 
(2005) were able to demonstrate neutralizing antibodies and reduced SARS-CoV 
loads in spike protein vaccinated mice.  
DNA vaccines targeting the spike (S) protein and the nucleocapsid (N) proteins were 
used for SARS-CoV (Woo et al., 2005b; Yang et al., 2004; Zhao et al., 2005). Here, 
viral genes that encode the antigenic compound are directly injected or otherwise 
inoculated into the vaccinee and the antigen is produced in the host cells. DNA 
vaccines expressing the SARS-CoV-S were able to induce neutralizing antibodies, 
whereas DNA vaccines that encode the N protein induced cell-mediated immunity but 
were not protective after high titer challenge. Furthermore, induction of delayed-type 
hypersensitivity was observed (Zhao et al., 2005). 
Vector vaccines rely on a host viral genome that is genetically modified to encode for 
antigens of the pathogen of interest. Some of the used vector systems have strong 
inherent adjuvant activities and can efficiently induce innate and B cell- as well as T 
cell-mediated immune responses. For delivering SARS-CoV-S or -N genes vesicular 
stomatitis virus (Kapadia et al., 2005), rhabdovirus (Faber et al., 2005), parainfluenza 
virus (Bukreyev et al., 2004) and vaccinia virus (Bisht et al., 2004; Chen et al., 2005) 
were used as vector systems. Especially, the modified vaccinia virus Ankara (MVA) 
has widely been used for the vaccine development against human diseases (Volz and 
Sutter, 2013). 
3 Modified Vaccinia virus Ankara (MVA) 
MVA was derived from the vaccinia virus strain Ankara that was used in Turkey for 
vaccination against smallpox. The virus got attenuated by over 570 serial passages in 
chicken embryo fibroblast cells (CEF) (Mayr, 1975). Genomic studies demonstrated 
that long-term passages resulted in the loss of approximately 15% of the MVA 
genome compared to the parental chorioallantois vaccinia virus Ankara (CVA) strain 
(Meyer et al., 1991). Six large genomic deletion sites as well as many shorter 
deletions, insertion and point mutations, resulting in gene fragmentation, truncation, or 
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deletions of open reading frames (ORFs) (Antoine et al., 1998; Meisinger-Henschel et 
al., 2007) have been identified. Due to these deletions and disruptions, the host range 
genes, like K1L and C12L/SPI-1 gene, the immunomodulatory proteins (Blanchard et 
al., 1998) (such as the functional receptors for TNF, IFN-α, IFN-β/γ and CC 
chemokine) and also some structural proteins (such as the major protein of the A-type 
inclusion body) are heavily affected by the genomic changes. All the serial changes 
contribute to the replication deficiency of the virus in human cells and its avirulence in 
animals (Mayr et al., 1978).This high-level attenuation was a key property that allowed 
for an extended use of MVA in human clinical applications.  
In addition to the high safety profile, the main reasons for the general appreciation of 
poxvirus vectors include the following features: (i) high genetic stability of the vector 
viruses, (ii) the viruses can accommodate large amounts of heterologous DNA, (iii) 
versatility for expression of many foreign proteins, and (iv) ability to stimulate high 
levels of humoral and cellular immune responses when used as recombinant vaccine.  
High genetic stability of MVA 
The genetic stability of a vector virus is determined by the stability of the viral genome 
and the stability of the recombinant gene sequences. Concerning the viral genome, 
the five genomic sequences of MVA, which were independently isolated in different 
laboratories (original description, the Acambis 3000 strain deposited from CDC, MVA-
I721 and MVA-BN deposited by Bavarian-Nordic GmbH), are confirmed to be identical 
(with the exception of the variable-length terminal repeat regions)(Antoine et al., 
1998). This result provides confirmation of Anton Mayr`s original conclusion that MVA 
can be considered genetically stable after 570 passages in CEFs (Mayr et al., 1975).  
About the stability of transgene sequences inserted into recombinant MVA, it must be 
considered recombinant gene products can exert a negative selective pressure on 
viral growth. Therefore, the rare mutants with reduced or altered expression of the 
foreign protein should be undetected, like the study about the recombinant MVA-BN 
(Timm et al., 2006), after 20 passages under selective conditions, RT-PCR results 
confirmed the transcription of the inserted genes. However, two cases about the 
instability of HIV Env have been reported independently by two groups (Burgers et al., 
2008; Wyatt et al., 2008). To avoid instability of the flanking regions of insertion sites 
and to prevent frame shifts in recombinant genes observed at consecutive runs of C or 
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G bases it was proposed to design recombinant MVA using codon optimization by 
gene synthesis and insertion of heterologous sequences between two essential genes 
(Wyatt et al., 2009). Also overexpression of a heterologous protein may result in 
instability, for example because of toxicity of the gene product to the cells. Here, use 
of the modified H5 promoter has been proposed to improve stability of the MVA vector 
while high level immunogenicity of the genetically engineered MVA vaccine is 
maintained (Wyatt et al., 1996). 
Packaging capacity for large amounts of heterologous DNA and versatile gene 
expression  
As a member of the orthopoxviruses with double-stranded DNA genomes, MVA 
encodes for a multitude of proteins required for virus replication. Unlike other DNA 
viruses, poxviruses exclusively replicate in the cytoplasm of host cells. This specific 
feature makes the viruses independent from the host cell genome and poxvirus gene 
expression is typically controlled by virus-specific promoters and virus-specific 
transcriptional machinery. Therefore, genes do not contain introns and mRNAs are not 
spliced (Tolonen et al., 2001). 
One interesting feature of poxviruses, including MVA, is their genetic plasticity which 
allows large amounts of foreign DNA (at least 25 kb) to be incorporated without loss of 
infectivity or reduction of gene expression. Methodologies leading to the generation of 
recombinant MVA vectors are well established (Kremer et al., 2012). Genomic 
insertion of heterologous gene sequences is mediated by homologous recombination 
between the viral DNA genome and the DNA from a shuttle plasmid that carries the 
gene sequence of interest under the transcriptional control of vaccinia virus (VACV)-
specific promoters.  
Stimulating high level of humoral and cellular immune responses 
The most important feature of the non-replicating MVA vaccines is their astonishing 
immunogenicity when compared to replication-competent VACV. In addition to the 
possibility that MVA may be particularly suitable for expression large foreign gene 
sequences, this observation can be well explained by the particular ability of MVA to 
present antigens in a favorable environment of infection providing for important innate 
responses and early activation of the host immune system (Delaloye et al., 2009; Halle 
et al., 2009; Lehmann et al., 2009).  
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MVA is known to trigger early migration of leukocytes to the site of infection (Lehmann 
et al., 2009). Dentritic cells (DC) are expected to be recruited at the inoculation site, to 
sample MVA-infected dying cells and following maturation to migrate to lymph nodes 
and activate antigen-specific T cells (Greiner et al., 2006; Pascutti et al., 2011). In this 
context, Price et al. (2013) recently summarized the strong immunostimulatory 
capacities of MVA targeting various components of the innate immune system. This 
data indicates that recombinant MVA vaccines do not just serve for production of 
antigen but also function as intrinsic adjuvant systems. 
An element becoming increasingly important for an efficient presentation is the stability 
of the expressed immunogen. The capacity of MVA vectors to elicit high levels of both 
humoral and cellular immune responses was shown upon evaluation of the first 
recombinant MVA vaccine that delivered the influenza virus HA and NP antigens 
(Sutter et al., 1994). Gasteiger et al. (2007) proposed that an immunogen produced by 
MVA as long-lived mature protein is the optimal substrate for efficient priming of 
antigen specific cytotoxic T cells (CD8+ T cells). The capacity to induce T cell 
mediated immunity was particularly well established with MVA candidate vaccines 
directed against immunodeficiency virus infections including human AIDS (Drexler et 
al., 2004; Sutter and Haas, 2001). Overall these observations strongly support the fact 
that recombinant MVA can serve as efficient vaccines to induce high T cell responses 
against various infectious agents and tumor antigens.  
Draper et al. (2013) recently summarized the data about the substantial potential of 
recombinant MVA to induce antigen-specific antibodies in both preclinical and clinical 
studies. The vaccine regimens tested were often based on heterologous prime-boost 
schedules with priming immunizations using a DNA vaccine or an adenovirus vector 
and the booster immunization with recombinant MVA vaccines. It can be assumed that 
the inherent adjuvant effect of the MVA vector vaccine provides for the strong booster 
responses and broader specificity of the antibodies as observed in many of these 
heterologous prime-boost studies. 
The history of the use of MVA vaccines in humans  
MVA was originally generated as attenuated vaccine against smallpox (Mayr, 1975; 
Mayr et al., 1978) and has subsequently been developed as vector to induce immune 
responses against a transgenic antigen (Moss, 1996; Sutter and Moss, 1992; Sutter 
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and Staib, 2003; Sutter et al., 1994). Until 1980, the non-recombinant MVA has been 
safely used in Germany to vaccinate more than 100,000 individuals for prophylaxis of 
smallpox, mostly in combination with conventional smallpox vaccine (Mayr, 1999). In 
2013, MVA was licensed as stand-alone third generation smallpox vaccine in Europe 
(EMA/490157/2013; EMEA/H/C/002596). 
In addition to its use as a vaccine against variola virus infections, the high safety 
profile of the virus spurred the use of MVA as recombinant vaccine in humans for 
prevention or therapy of important infectious diseases and cancer. The first published 
clinical studies with recombinant MVA targeted malaria, AIDS or breast cancer 
(Cosma et al., 2003; Moorthy et al., 2003; Rochlitz et al., 2003). Current clinical trials 
include various phase I and phase II studies also targeting other important human 
diseases such as hepatitis B, hepatitis C, and influenza (Table 3) (Kreijtz et al., 2013). 
Until now, several thousand individuals including children have been vaccinated with 
various recombinant MVA vaccines and no serious adverse events have been 
reported (Gilbert, 2013; Gomez et al., 2013).  
 
Target 
disease 
Antigen 
Stage 
(phase) 
Safe Immunogenic Reference 
AIDS 
HIV-1 Env      
HIV A gag/pol 
I/II yes yes Bakari et al., 2011 
HIV-1 Nef I/II yes yes Cosma et al., 2003 
HIV-B 
env/gag/pol/nef I/II yes yes 
Gomez et al., 2011 
Garcia et al., 2011 
Hepatitis B HBV S I yes yes Cavenaugh et al., 
2011 
Hepatitis C HCV NS3,        
NS4 and NS5B II yes yes Wedemeyer H, 2011 
Human 
papilloma 
HPV16            
E6 and E7 II yes yes Albarran et al., 2007 
Influenza NP and M1 I/II yes yes 
Berthoud et al., 2011 
Lillie et al., 2012 
Antrobus et al., 2012 
Table 3 Clinical evaluation of recombinant MVA vaccines for viruses                         
(from Kreitz et al., 2013; modified) 
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4 Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 
In June and September 2012, almost ten years after the SARS pandemic, health 
authorities recognized two human patients from the Middle East with severe 
respiratory illness reminding of the pathogenesis of SARS. Both patients succumbed 
to acute pneumonia and renal failure. The causing agent was not SARS-CoV but a 
novel human coronavirus (Bermingham et al., 2012). The complete genome sequence 
of the novel coronavirus was obtained by the group of Ron Fouchier at the Erasmus 
Medical Center (EMC) in Rotterdam, The Netherlands. Therefore the new virus was 
first named “human coronavirus EMC” (hCoV-EMC)(van Boheemen et al., 2012). In 
May 2013, the Coronavirus Study Group of the International Committee on Taxonomy 
of Viruses (ICTV) renamed the virus “Middle East respiratory syndrome coronavirus” 
(MERS-CoV)(de Groot et al., 2013). In the meantime the newly discovered virus 
became an important emerging pathogen in the Middle East (Figure 3).  
 
Figure 3 Cumulative MERS-CoV cases and deaths and proportion of fatal cases 
(http://virologydownunder.blogspot.de) 
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Globally, from September 2012 to the time of writing, WHO has been informed of a 
total of 189 laboratory-confirmed cases of infection with MERS-CoV, including 82 
deaths (http://www.who.int/csr/don/2014_03_12/en/). MERS-CoV infection causes 
atypical pneumonia, an acute respiratory distress syndrome (ARDS) and sometimes 
renal failure, which often causes the death of the patient. Because of the low number 
of confirmed cases, the mortality rate cannot be accurately estimated. There are also 
reports that MERS-CoV infection can even be asymptomatic or causes only mild 
disease (Assiri et al., 2013a; Assiri et al., 2013b; Memish et al., 2013).   
Virological characteristics of MERS-CoV 
Coronaviruses are pleomorphic, enveloped, single-stranded, positive sense RNA 
viruses. They are widespread in many different species of birds and mammalians and 
may cause respiratory, enteric, hepatic, or neurologic disease, with variable severity in 
various animal species (Perlman and Netland, 2009).  
Based on genome sequence analysis, the ICTV has divided the family coronaviridae 
into four genera, named alpha-, beta-, gamma-, and deltacoronavirus. Furthermore, 
the genus alphacoronavirus contains two (a and b) and the genus betacoronavirus 
contains four (a, b, c, d) different lineages. The two human coronaviruses hCoV-229 
and hCoV-NL63, which were identified in the 1960s and caused mild common colds, 
belong to the genus alphacoronavirus. SARS-CoV is a lineage B betacoronavirus and 
the lineage A of genus betacoronavirus includes hCoV-OC43 and hCoV-HKU1, which 
were discovered subsequently after the SARS-CoV (Fouchier et al., 2004; van der 
Hoek et al., 2004; Woo et al., 2005a). The genera gamma- and deltacoronavirus 
contain only viruses that infect animals. However, the phylogenetic analysis performed 
by Zaki et al. (2012) showed that, together with the bat coronavirus BtCoV-HKU4 and 
BtCoV-HKU5, the MERS-CoV belongs to the lineage c of betacoronavirus (Figure 4). 
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Figure 4 Phylogenetic tree (maximum likelihood) of representative coronaviruses 
(from Graham et al., 2013, with permission) 
 
The MERS-CoV genome contains 30119 nucleotides and at least ten open reading 
frames (ORFs) (Figure 5). The whole genome includes ORF1a and ORF1b as well as 
(at least) nine downstream ORFs. ORF1a and ORF1b are two large ORFs and 
responsible for the production of the polyproteins (pp1a and pp1ab), which occurs via 
ribosomal frame shifting at the junction between the two ORFs. Downstream of 
ORF1b the genome harbors the small ORFs encoding for the structural proteins spike 
(S), envelope (E), membrane (M), and nucleocapsid (N). Between the S and E genes, 
four additional small ORFs are located, named 3a, 3b, 3c, and 3d and presumed to, 
encode for non-structural proteins. This genome organization was found to be similar 
to that of the bat coronaviruses BatCoV-HKU4 and BatCoV-HKU5, once more 
confirming the similarity among these three viruses (Hofmann et al., 2005; Li et al., 
2003). 
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Figure 5 Genome organization of MERS-CoV                                                        
(from Boheemen et al., 2012, with permission) 
 
The MERS-CoV virion structure is shown in Figure 6. The spike (S) protein of 
coronaviruses is responsible for the binding to the host cell receptor and determines 
the viral host and tissue tropism (Belouzard et al., 2012). The cell surface molecule 
DPP4 (dipeptidyl peptidase-4, also known as CD26), has been identified as the 
functional cellular receptor for MERS-CoV (Raj et al., 2013). This seems to be a virus-
specific receptor, in contrast to the angiotensin-converting enzyme 2 (ACE2), being 
used by the SARS-CoV and hCoV-NL63 (Hofmann et al., 2005; Li et al., 2003). After 
the DPP4 was confirmed as the receptor of MERS-CoV, the receptor binding domain 
(RBD) has also been mapped (Jiang et al., 2013; Mou et al., 2013). The RBD-S 
interaction falls with residues 358-662 of the S1 domain and antibodies to this domain 
were observed to efficiently neutralize MERS-CoV infection. Upon binding, the viral 
entry of MERS-CoV involves virus-cell fusion, which can be activated by type II 
transmembrane serine proteases TMPRSS2 (Shirato et al., 2013). 
The envelope (E) and membrane (M) proteins are small transmembrane proteins 
associated with the envelope of all coronaviruses. Like the conserved proteins 
encoded by ORF1ab, the nucleocapsid gene (N) gene is also another common target 
for phylogenetic analysis. Due to its immunogenicity, it is also a common target for 
cloning and generation of recombinant proteins for serological assays (Woo et al., 
2010). 
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Figure 6 Coronavirus virion structure and proteins                                                 
(from Graham et al., 2013, with permission) 
 
Epidemiology of MERS-CoV 
MERS-CoV infections have been reported from countries in the Middle East including 
Jordan, Kingdom of Saudi Arabia (KSA), the United Arab Emirates (UAE), Kuwait, 
Oman, and Qatar. In Europe affected countries include France, Germany, the United 
Kingdom (UK), Italy and North Africa Tunisia (CDC; http://www.cdc.gov/coronavirus/ 
MERS/) (Figure 7). 
Overall, the average age of MERS-CoV confirmed cases is 50 years, ranging from 14 
months to 94 years, and 64% of patients were male. Among all confirmed cases, there 
were 18 asymptomatic cases, 30% had non-severe disease, while 64% of patients 
were reported to suffer from severe pneumonia with the ARDS, septic shock and 
multi-organ failure, even resulting in death. The development of the disease usually 
starts with fever and cough, chills, sore throat, myalgia and arthralgia, followed by 
dyspnea and rapidly progresses to pneumonia, often requiring automated ventilation 
and other organ support (Assiri et al., 2013a; Assiri et al., 2013b). 
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Figure 7 Geographic distribution of human MERS-CoV infections                            
(from http://www.uq.edu.au/vdu/VDUMERSCoronavirus.html) 
 
The confirmation of virus reservoir and infection source is the key for emerging 
infection prevention and control. The fact that the reported MERS-CoV infections 
appear to be sporadic and epidemiological unlinked suggests that MERS-CoV is a 
zoonotic virus, as reported for other known coronaviruses (To et al., 2013). The 
phylogenetic proximity of the virus with the bat coronavirus further supports this 
suggestion. 
Until now, the pathways used by MERS-CoV for interhuman transmission are still 
unknown. Generally, coronavirus are transmitted among humans via aerosol droplets 
and/or through direct contact with other secretions (stool, urine etc.) (Danielsson et al., 
2012). Several case investigations have suggested that airborne transmission seems 
to be the mostly likely route (Guery and van der Werf, 2013; Mailles et al., 2013; 
Memish et al., 2013). Furthermore, given the high concentration of the virus in the 
lower respiratory tract of infected patients, airway suctions or the use of 
bronchoscopes could also serve as a source of transmission (Guberina et al., 2014). 
The fecal-oral route is likely also important for transmission because of the infectivity 
in urine and stool samples of patients and given the fact that patients from the same 
cluster of infection had been sharing toilet rooms during hospitalization. Transmission 
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via blood should also be considered as a possible route since some reports claim that 
the virus might be present in blood. This observation might be correlated to the 
reported person-to-person transmission in hemodialysis unit of a hospital in Saudi 
Arabia (Assiri et al., 2013b). 
When investigating the source of MERS-CoV infection the high similarity of MERS-
CoV to BtCoV-HKU4 and BtCoV-HKU5 was recognized upon first phylogenetic 
analyses of virus genome sequences. Therefore, it was assumed that bats could be 
the source of infection, especially since the Arabic peninsula harbors a number of 
various bat species. The observation that MERS-CoV was able to infect cells derived 
from bat family support this theory. However, direct contact between humans and bats 
is rather unusual and no such contact has been reported for one of the MERS patients 
(Chan et al., 2013b). The DPP4 residues responsible for contact with the RBD of the 
MERS-CoV S protein are highly conserved among different species, including 
macaques, pigs, and rabbits. This data would imply that MERS-CoV is able of 
infecting multiple host organisms (Wang et al., 2013). This hypothesise was further 
supported by the fact that MERS-CoV can also infect primate and porcine cell lines in 
vitro (Bosch et al., 2013).  
Based on the above observations, scientists are currently in search of a possible 
intermediate host that can be the direct source of MERS-CoV infection. In a recent 
study, sera of sheep, cattle, goat, camels and other camellia species from Middle 
East, Spain, Netherlands, and Chile were tested for the presence of antibodies against 
the S protein of MERS-CoV. Interestingly, it was found that 100% of the camels from 
the Middle East and 14% of the Spanish camel sera were positive and with high titers. 
No anti-MERS-CoV antibodies were found in any of the other animal species tested 
(Reusken et al., 2013). Indeed, for some of the MERS patients, contact with camels 
had been reported (Chan et al., 2013b; Drosten et al., 2013). Most recently Alagaili et 
al. (2014) detected MERS-CoV in nasal and rectal swabs of juvenile dromedary 
camels from the Kingdom of Saudi Arabia, indicating their role as potential reservoir 
for human transmission.  
In order to assess the transmissibility of the virus, two groups estimated the basic 
reproduction number R0, which is the number of secondary cases that one case would 
produce in a completely susceptible population. The results of this study suggested 
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that the transmission rate of MERS-CoV among humans is still low and that the virus 
does not have pandemic potential yet (Breban et al., 2013; Cauchemez et al., 2014). 
Diagnosis of MERS-CoV Infection 
With no MERS-CoV-specific test established, the samples from the index case from 
Kingdom of Saudi Arabia were tested by a pan-coronavirus PCR (Zaki et al., 2012). 
This assay targets highly conserved regions of the RNA-dependent RNA polymerase 
gene, and is used to detect all known and unknown coronavirus (Vijgen et al., 2008). 
After the MERS-CoV was identified, different real time RT-PCR assays for routine 
detection of MERS-CoV have been developed within a short time, targeting the upE 
region, the ORF1b and the Orf1a (Chan et al., 2013a; Corman et al., 2014). All these 
assays were confirmed by excluding cross-reactivity with the other known human 
coronaviruses. In addition, the US Centers for Disease Control and Prevention (US 
CDC) has developed RT-PCR assays targeting the MERS-CoV nucleocapsid (N) 
protein gene, which can complement the other assays for screening and confirmation.  
The selection of the appropriate clinical specimens that will be tested for the presence 
of the virus is of high importance. However, it is not yet clear, when MERS-CoV 
shedding peaks or which body fluids are most likely to yield enough viruses to be 
tested positive. Therefore, based on the fact that MERS-CoV preferably replicates in 
cell lines which derived from the lower respiratory tract and the clinical image of the 
MERS-CoV patients indicates lower respiratory tract involvement (Chan et al., 2013a; 
Chan et al., 2012), the CDC recommends that lower respiratory tract specimens 
(sputum, broncho alveolar lavage fluid, or endotracheal aspirate) should be tested for 
MERS-CoV. This recommendation was further supported by the fact that 
nasopharyngeal swabs of suspected MERS-CoV patients were found negative, while 
lower respiratory tract specimens obtained from the same patients were positive 
(Guery et al., 2013). 
Serology can provide valuable information on rates of infection in populations, and 
serological surveys, particularly among known risk groups or populations. Corman et 
al. (2012) proposed to detect antibody response against MERS-CoV by 
immunofluorescence microscopy based on the fact that putative anti-MERS-CoV 
antibodies in convalescent patient serum could recognize and bind to viral antigens 
inside MERS-CoV-infected cell lines. However, Chan et al. (2013c) reported that the 
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presence of cross-reactive neutralizing antibodies against MERS-CoV in the serum of 
convalescent SARS patients made the specificity of this assay questionable. 
Therefore, this assay cannot be used independently and has to be confirmed by 
neutralization test. A highly specific assay for detection of MERS-CoV antibodies using 
protein microarray technology has also been developed by Reusken et al. (2013). This 
assay can detect the IgM and IgG antibodies against the receptor binding spike 
domain S1 and has no cross-reactivity within all known human coronavirus assay. 
Therefore, this serological assay is available and with great value for human and 
animal population screening, both of which are necessary to gain insight into the 
epidemiology of the novel coronavirus. In addition, US CDC has developed a two-
stage approach to detect antibodies against MERS-CoV, based on a screening test 
using a recombinant nucleocapsid (N) protein-based indirect enzyme-linked 
immunosorbent assay (ELISA), followed by a confirmatory test using a whole-virus 
indirect fluorescent antibody (IFA) test or neutralization test. 
Treatment of MERS-CoV infection 
Even ten years after the SARS pandemic there are currently no approved antiviral 
treatments for human coronavirus infections, including SARS-CoV and MERS-CoV 
(Graham et al., 2013). So, the current patient management largely depends on 
provision of organ support, and vigilance for and prevention of complication. In specific 
circumstances, additional interventions have included empiric use of broad-spectrum 
antimicrobial agents, antivirals and anti-fungal agents to minimize risk of co-infections 
with opportunistic pathogens (Chan et al., 2012).  
The high mortality associated with MERS-CoV drives the research on potential 
therapeutic agents. So far, studies have evaluated the effect of interferon (IFN), 
receptor binding domain (RBD) and DPP4 on the viral replication (Table 4). The fact 
that MERS-CoV infection does not induce IFN response in human cell lines spurred 
further investigations (Chan et al., 2013c; Zielecki et al., 2013). The anti-viral effect of 
IFN-α, IFN-λ3, pegylated IFN-α, and IFN-β has been investigated in vitro by different 
groups (de Wilde et al., 2013; Falzarano et al., 2013; Kindler et al., 2013). It was 
concluded that high concentrations of each of the interferon compounds alone are 
needed to mediate an anti-viral effect (demonstrated by reduced cytopathic effect 
(CPE) and viral protein levels). Combinations of interferons, however, can yield an 
anti-viral effect even when lower concentrations are used. 
Literature   20 
 
The viral attachment and viral membrane fusion with the host cell membrane are 
essential for the cellular entry of enveloped viruses and are therefore targets of anti-
viral therapeutic strategies. The spike protein has been showen to mediate the binding 
with the receptor of cells for all coronavirus. Since the RBD was mapped at the C-
terminal part of S1 subunit, Chen et al. (2013) and Du et al. (2013a) investigated the 
possible therapeutic implication of this domain, and showed that the RBD can 
efficiently inhibit the MERS-CoV entry. A previous study reported that DPP4 serves as 
the functional receptor for MERS-CoV (Raj et al., 2013). Raj et al. also described that 
the adenosine deaminase (ADA), a DPP4 binding protein, could compete for virus 
receptor binding. Thus ADA might be used as a natural antagonist for MERS-CoV 
infection (Raj et al., 2014).  
Drug 
candidate Target In vitro effect Reference 
IFN-α 
Interferon 
Reduction of MERS-CoV replication in 
pseudo-stratified HAE cultures 
Kindler et al., 
2013 
Pegylated 
IFN-α 
Inhibition of MERS-CoV induced CPE and 
reduction of the viral RNA levels in human 
lung epithelial and 
monkey kidney cell lines 
de Wilde et al., 
2013 
IFN-β 
Reduction of the viral load in MERS-CoV 
infected human lung epithelial and monkey 
kidney cell lines 
Zielecki et al., 
2013 
IFN-λ3 Reduction of MERS-CoV replication in 
pseudo-stratified HAE cultures 
Kindler et al., 
2013 
IFN-α2b 
Reduction of the MERS-CoV induced CPE 
and the viral protein levels in monkey 
kidney cell lines  
Falzarano et al., 
2013 
Adenosine 
deaminase 
(ADA) 
Dipeptidyl 
peptidase-
4 (DPP4) 
ADA blocks MERS-CoV binding and 
infection Raj et al., 2014 
MERS-CoV 
RBD 
Receptor 
binding 
domain 
(RBD) 
Reduction of the viral load in a MERS-CoV 
infected monkey kidney cell lines Chen et al., 2013 
 
Tabelle 4 Drug candidates with in vitro effects on MERS-CoV replication 
 
Although some studies already showed promising anti-MERS-CoV results in vitro, the 
experience with SARS-CoV teach us that it may take a long time until an etiological 
treatment is available. Therefore, the development of safe, stable vaccines is 
necessary (Graham et al., 2013).  
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III. OBJECTIVES 
Due to the very recent emergence of the Middle East respiratory syndrome 
coronavirus there is no etiological treatment or vaccine available. Therefore this work 
describes: 
(i) the generation of a recombinant MVA expressing the spike protein of 
MERS-CoV, 
(ii) genetic analysis of the recombinant MVA, 
(iii) analysis of the expressed spike protein, 
(iv) vaccination experiment in mice 
(v) characterization of induced neutralizing antibodies. 
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IV. RESULTS 
The manuscript is presented in the form accepted for publication. 
It has its own reference section formatted in the style of the journal. References and 
abbreviations from the manuscript are not included in the relevant section at the end of 
this document.  
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Middle East respiratory syndrome coronavirus (MERS-CoV) has recently 
emerged as a causative agent of severe respiratory disease in humans. Here, we 
constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-
length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and 
growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for 
clinical testing. Vaccinated mice produced high levels of serum antibodies 
neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development 
of an emergency vaccine against MERS-CoV. 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a novel infectious agent 
causing severe respiratory disease and deaths in humans, was first described in 2012 
(1-3). To date a total of 108 cases of infection with MERS-CoV have been confirmed, 
including 50 deaths (http://www.who.int/csr/don/2013_08_30/en/index.html). Most 
infections were geographically linked to the Middle East, i.e. Jordan, Saudi Arabia, 
Qatar, and United Arab Emirates, but cases also occurred in the United Kingdom, 
Germany, France and Italy. The epidemiology of MERS-CoV infection remains 
unclear. The virus is suspected to persist in animal reservoirs and cause zoonotic 
infections in humans (4, 5). The MERS-CoV spike (S) protein, a characteristic 
structural component of the virion membrane, forms large protruding spikes on the 
surface of the virus; its S1 domain mediates binding to dipeptidyl peptidase 4, which 
serves as the host cell receptor of MERS-CoV (6). Importantly, the S protein is 
considered a key component of vaccines against coronavirus infection, including 
severe acute respiratory syndrome (SARS) (7, 8).  
Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus 
originating from growth selection on chicken embryo fibroblasts (CEF), shows a 
characteristic replication defect in mammalian cells (9, 10, 11). At present, MVA 
serves as one of the most advanced recombinant poxvirus vectors in preclinical 
research and human clinical trials for developing new vaccines against infectious 
disease and cancer (12, 13, 14).  
Here, we show that the full-length S protein of MERS-CoV, expressed by MVA, is 
produced as an ~210-kDa N-glycosylated protein that is specifically recognized by 
antibodies in Western blot analysis. Further studies suggest cleavage of the mature 
full-length S glycoprotein into an amino-terminal domain (S1) and an ~85-kDa 
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carboxy-terminal domain (S2) that is putatively anchored to the membrane. When 
tested as a vaccine in mice, recombinant MVA expressing the S protein induced high 
levels of circulating antibodies that neutralize MERS-CoV in tissue culture infections. 
Construction and characterization of recombinant MVA. cDNA containing the 
entire gene sequence encoding MERS-CoV S (GenBank accession no. JX869059) 
was obtained by DNA synthesis (Invitrogen Life Technology, Regensburg, Germany) 
and modified by introducing silent mutations that remove three termination signals 
(TTTTTNT) for vaccinia virus transcription (MERS-S). Furthermore we generated a 
second version containing a tag sequence encoding nine amino acids (YPYDVPDYA) 
from influenza virus hemagglutinin (HA tag) attached at the C-terminus of S (MERS-
SHA). MERS-S and MERS-SHA were cloned under the transcriptional control of the 
vaccinia virus early/late promoter PmH5 (15) and introduced by homologous 
recombination into an existing deletion site (deletion III) in the MVA genome (Fig. 1A).  
MVA expressing MERS-S or MERS-SHA (MVA-MERS-S or MVA-MERS-SHA, 
respectively) were obtained using standard methods to generate recombinant MVA 
vaccines suitable for clinical testing, as described previously (13). Briefly, transient 
coproduction of the fluorescent marker protein mCherry (under control of the vaccinia 
virus late promoter P11 (16) was used to isolate clonal recombinant viruses by 
screening for fluorescent cell foci during repetitive plaque purification. At this stage, 
immunostaining of infected cell cultures with anti-HA tag monoclonal or polyclonal 
antibodies from MERS-CoV-infected macaques suggested synthesis of the 
recombinant SHA and S proteins in CEF and Vero cells (ATCC CCL-81) (Fig. 2). MVA-
MERS-S and MVA-MERS-SHA were genetically stable and replicated efficiently in 
CEF, but not in human HeLa or HaCat cells (Fig. 1 B and C). The latter findings 
confirmed that the recombinant viruses could be handled under biosafety level 1 
conditions.  
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FIG 1 Generating and characterizing recombinant MVA. (A) Schematic diagram of 
the MVA genome and the locations of major deletion sites I to IV, with deletion III 
being the site used to insert the MERS-CoV S gene sequences. Flank-1 and flank-2 
refer to MVA DNA sequences adjacent to deletion site III which were originally 
prepared by PCR and cloned into MVA transfer plasmids targeting deletion site III for 
insertion of recombinant genes. In MVA vector plasmids pIIIH5red-S and -SHA, the S 
coding gene sequences (MERS-S/SHA) are placed under transcriptional control of the 
vaccinia virus promoter PmH5 and introduced by homologous recombination between 
the flanking sequences in the vector and the MVA genome. MVA-MERS-S and MVA-
MERS-SHA were isolated in plaque passages by screening for transient co-expression 
of the fluorescent marker gene mCherry under transcriptional control of the vaccinia 
virus late promoter P11. Repetitive sequences (del) are designed to remove the 
mCherry marker by intragenomic homologous recombination (marker gene deletion). 
(B) Genetic integrity and genetic stability of MVA-MERS-S and MERS-SHA. PCR 
analysis of genomic viral DNA using oligonucleotide primers to confirm the identity 
(MERS-S) and proper insertion (deletion III) of S gene sequences. (C) Multiple-step 
growth analysis of recombinant MVA-MERS-S. Recombinant MVA (MVA-S) and 
wildtype MVA (MVA) can be efficiently amplified in CEF (multiplicity of infection 
[MOI,]0.1) but fail to productively grow in HeLa and HaCat human cell lines. 
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FIG 2 Immunostaining of S proteins in recombinant MVA-infected cells. (A) 
Transient expression of the marker protein mCherry served to localize single virus 
infected cells (left panel). Monoclonal antibody directed against the HA-tag (anti-HA) 
(right panel) reveals the presence of SHA in Vero cells infected (MOI, 0.1) with MVA-
MERS-SHA (MVA-SHA). (B) Polyclonal antibodies from a MERS-CoV-infected 
cynomolgous macaque (anti-MERS-CoV) detected S-producing cell foci in CEF 
infected with MVA-MERS-S (MVA-S; MOI, 0.1) but no foci when CEF were infected 
with nonrecombinant MVA (MVA). 
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Characterization of MERS-CoV S expressed by recombinant MVA. We specifically 
detected a protein with an estimated molecular mass of about 200 kDa in lysates from 
MVA-MERS-S and MVA-MERS-SHA infected Vero cells using sera from MERS-CoV 
infected macaques in Western blots (Fig. 3A, upper panel). Further immunoblot 
analysis with monoclonal anti-HA tag antibody (Roche, Penzberg, Germany) 
confirmed the production of a protein doublet of 200 to 210 kDa in cells infected with 
MVA-MERS-SHA as well as a second protein of about 85 kDa (Fig. 3A, lower panel).  
The molecular masses of the 200- to 210-kDa polypeptides detected by SDS/PAGE 
were significantly higher than the 149 kDa predicted for MERS-CoV S protein based 
on its nucleotide sequence. NetNGlyc server analysis suggested at least 17 likely N-
glycosylation sites (Asn-X-Ser/Thr) for co- and post-translational modification. 
Therefore, we investigated the glycosylation pattern of the expressed SHA protein 
using treatment with peptide-N-glycosidase F (PNGase F) or endoglycosidase H 
(Endo H) (both from New England Biolabs) followed by Western blot analysis 
(Fig. 3B). SHA produced in MVA-MERS-SHA infected Vero cells was treated with 
PNGase F, which removes all N-linked oligosaccharide chains from glycoproteins. 
This treatment reduced the ~210-kDa protein doublet to a sharp protein band of 150-
kDa, a value closely matching the predicted mass of unmodified MERS-CoV S protein.  
Similarly, PNGase F treatment converted the 85-kDa protein fragment to a polypeptide 
with 55 kDa. Endo H cleaves N-linked high-mannose oligosaccharides synthesized in 
the endoplasmic reticulum, but not those matured to more complex oligosaccharides 
in the Golgi apparatus. Western blot analysis of SHA digested with endo H revealed a 
band of 150 kDa proteins, indicating complete hydrolysis of N-linked oligosaccharides. 
An additional subpopulation of SHA migrated with the original size of about 210 kDa 
indicating resistance to endo H treatment. Of note, the 85 kDa protein subpopulation 
remained largely unaffected by endo H digestion. 
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FIG 3 Synthesis of full-length S glycoprotein in recombinant MVA-infected cells. 
(A) Western blot analysis of cell lysates from MVA-MERS-S (MVA-S)- or MVA-MERS-
SHA (MVA-SHA)-infected Vero cells 24 h postinfection. Polypeptides were analyzed by 
SDS-PAGE and immunoblotting using serum from a MERS-CoV-infected macaque 
(1:1000, upper panel) or monoclonal rat anti-HA-tag antibody (1:50; lower panel). 
Lysates from uninfected (Vero) or wild-type MVA-infected (MVA) cells served as 
controls. (B) Western blot analysis of MVA expressed SHA following treatment with 
glycosidases. Vero cells were infected with MVA-MERS-SHA for 24 h. Cell lysates were 
incubated with (+) or without (-) glycosidase PNGase F or endo H and analyzed by 
SDS-PAGE and immunoblotting with monoclonal rat anti-HA-tag antibody (1:50). 
Numbers on the left indicate molecular masses of marker proteins in kilodaltons.  
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Immunogenicity of MVA-MERS-S in mice. BALB/c mice were vaccinated 
intramuscularly with 108 pfu MVA-MERS-S at 0 and 3 weeks. Twenty days after the 
first immunization, and ten days after the second immunization sera samples were 
tested for their capacity to neutralize MERS-CoV (EMC isolate) in tissue culture 
infections using 200 50% tissue culture infective doses (TCID50) in Vero cells or 100 
TCID50 in Huh-7 cells. Even a single application of MVA-MERS-S induced low levels of 
virus-neutralizing antibodies in all eight animals tested (Fig. 4A). After booster 
immunization all vaccinated animals produced high levels of circulating antibodies that 
neutralized MERS-CoV (Fig. 4B and C). In contrast, neutralizing antibodies were not 
detected in sera samples from control animals inoculated with non-recombinant MVA 
or saline (phosphate buffered saline [PBS]). The specificity of the induced MVA-
MERS-S antibodies for MERS-CoV was confirmed by the absence of detectable 
neutralization against SARS coronavirus (SARS-CoV) (strain HKU39849) (Fig. 4D). In 
addition, the MERS-CoV-neutralizing activity of these sera could be only partly 
blocked by preincubation with proteins that encompass the receptor binding domain 
(RBD) (Fig. 4E and F). The latter observation is consistent with the fact that besides 
the RBD other parts of the spike protein are able to induce neutralizing antibodies 
(17). 
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FIG 4 Antibody responses after intramuscular immunization with recombinant 
MVA-MERS-S. BALB/c mice (n = 10) were vaccinated twice within a 21-day interval 
with 108 pfu MVA-MERS-S (MVA-S). Groups of mice (n = 4) vaccinated with wild-type 
MVA (MVA) or saline (PBS) served as controls. MERS-CoV virus-neutralizing titers 
(VNT) were determined 20 days after primary immunization (A) and 10 days after the 
second immunization (B and C) using Huh7 (A and B) and Vero cells (C). Sera 
obtained after the second boost were also tested against SARS-CoV on Vero cells 
(D). Serum from a rabbit (17) immunized with the MERS-CoV receptor binding domain 
(RBD) (E) or sera from mice obtained after the second MVA-S boost (F), were 
preincubated with PBS, the RBD, or a SARS-CoV-derived control protein (CTRL) at 5 
µg/ml for 1 h before incubation with MERS-CoV, followed 1 h later by inoculation on 
Vero cells. 
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Conclusions. Our objective was to use MVA vectors compatible with clinical 
evaluation to express mostly native S antigen to induce antibodies that would 
neutralize MERS-CoV. The S gene of MERS-CoV expressed by recombinant MVA 
produced a glycoprotein migrating at a molecular mass of about 210 kDa. Glycosidase 
treatment to remove all N-linked carbohydrates resulted in a polypeptide of 150 kDa, 
closely corresponding to the molecular mass predicted from the S gene nucleotide 
sequence. A subpopulation of protein apparently acquired endo H resistance, 
indicating trafficking of S to the Golgi apparatus, which correlates with observations 
made for SARS-CoV S protein (18, 19, 20).  
In addition, we obtained evidence for putative S1 and S2 cleavage of full-length S as 
predicted recently (6, 21). The HA-tag fused to the C-terminus of SHA enabled us to 
detect two glycoprotein subpopulations, full-length S (~210 kDa) and subdomain S2 
(~85 kDa), by anti-HA Western blot analysis (Fig. 3). We considered furin cleavage 
sites because spike proteins of some betacoronaviruses and all gammacoronaviruses 
are typically activated by intracellular furin-dependent cleavage (22, 23; for review see 
references 24, 25); the ProP1.0 server indicated three possible furin cleavage sites at 
amino acid positions 751, 887, and 1113 of MERS-CoV S (data not shown). We favor 
putative cleavage at amino acid 887 since this cleavage would produce a predicted S2 
subdomain of 54.5 kDa for the non-glycosylated protein matching our Western blot 
data (Fig. 3). Moreover, prominent endo H resistance of the 85-kDa S2 subdomain 
suggests that S cleavage occurs predominantly during or after passage through the 
Golgi apparatus.  
Since biochemical characterization of the MVA-expressed S suggested synthesis of a 
mature and properly folded spike antigen, we investigated whether MVA-MERS-S 
would elicit virus-neutralizing antibodies. Indeed, mice immunized with MVA-MERS-S 
via an intramuscular route developed circulating antibodies that neutralized MERS-
CoV infections in highly permissive tissue cultures. Interestingly, compared to results 
of previous studies eliciting neutralizing antibodies to SARS-CoV (18), MVA-MERS-S 
induced relatively high levels of antibodies that efficiently block MERS-CoV infection. 
This observation may be explained by MERS-CoV-specific differences in receptor 
usage and entry mechanisms, as discussed previously (18). Previous work with 
SARS-CoV showed that S-specific neutralizing antibodies correlated with the 
protective capacity of vaccination in various animal models (18, 26, 27; for a review 
see reference 28).  
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Future studies will be necessary to monitor for S antibody-dependent enhancement of 
MERS-CoV infections, as previously discussed for SARS-CoV and feline coronavirus 
infections (28, 29, 30). Furthermore, the safety and protective capacity of MVA/MERS-
S immunization should be tested in animal models that reproduce MERS-CoV 
infections in humans. However the current absence of suitable preclinical models 
recommends the development of an MVA vaccine delivering MERS-CoV-S.  
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V.  DISCUSSION 
In the light of the pandemic threat caused by MERS-CoV, the availability of sufficient 
doses of safe and effective vaccines is considered a priority. Our objective of this 
study was to express spike protein antigens in a native state to induce antibodies that 
would neutralize MERS-CoV by using the live-attenuated vector virus MVA. The newly 
constructed recombinant MVA-MERS-S can express the full-length MERS-CoV S 
protein coding sequences with the strong poxvirus-specific promoter PmH5. The 
recombinant virus MVA-MERS-S was genetically stable and was able to replicate in 
primary CEF cells to high titers (108 PFU/ml). Moreover, the maintained replication 
deficiency of the vector on mammalian cells support the view that MVA-MERS-S could 
serve as a safe vaccine for human and animal use. In addition, vaccinated mice 
produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-
S may serve for further development of an efficacious emergency vaccine against 
MERS-CoV.  
Why is a vaccine needed for prophylaxis against MERS-CoV ? 
Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly isolated human 
coronavirus which caused outbreaks of a SARS-like illness in the Middle East. Until 
now, WHO has been informed of 189 confirmed cases, including 82 deaths (a case 
fatality rate >40%) (http://who.int/csr/don/2014_03_12/en). Cases were reported 
mainly from four Middle East countries (Saudi Arabia, Jordan, Qatar and the United 
Arab Emirates), three European countries (Frances, Italy, and the United Kingdom), 
and one African country (Tunisia). Among all confirmed cases, eight clusters MERS-
CoV infectionshave been identified.The largest cluster of infections consisted of 25 
patients including 14 deaths. This finding of cluster infections strongly suggests the 
possibility of inter-human transmission of MERS-CoV. So far, the efficiency of human-
to-human transmission of MERS-CoV seems lower than the one observed during the 
SARS epidemic. However, MERS-CoV may gain increased human-to-human 
transmissibility after its further adaptation and evolution in human or as-yet unknown 
intermediate hosts. Therefore, MERS-CoV is threatening to eventually cause a global 
pandemic and thus, the epidemiology of MERS-CoV is closely watched by WHO and 
possible counter-measures are being considered by public health institutions. 
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To date, there are no approved antiviral treatments or vaccines against human 
coronaviruses, including SARS-CoV. Clinical management of MERS-CoV infected 
patients is mainly supportive placing emphasis on organ support for respiratory and 
renal failure. Vaccines are among the most cost-effective public health measurements 
and vaccines are core components of any preventive service package targeting 
infectious diseases. In consequence, the development of safe and efficacious 
vaccines against MERS-CoV and other emerging coronaviruses is highly desirable. In 
particular, it must be reflected that these viruses persist in heterogeneous pools, likely 
in various host species, and future vaccines would ideally be broad-spectrum or 
rapidly adaptable to newly emerging coronavirus pathogens. 
The spike protein of MERS-CoV - a suitable target antigen for vaccine 
development.  
Like other coronaviruses, the MERS-CoV virion utilizes a large surface spike (S) 
glycoprotein for interaction with and entry into the target cell. It has been reported that 
MERS-CoV uses a cell surface amino peptidase, DPP4, as a functional receptor 
(Jiang et al., 2013; Raj et al., 2013). Another group systematically characterized the 
MERS-CoV HR1/HR2 complexes and presented a 1.9 Å crystal structure of the viral 
fusion core. This result demonstrated that the spike protein of MERS-CoV can 
mediates the membrane fusion in a similar way as reported for other coronaviruses 
(Gao et al., 2013). The roles of the S protein in both receptor binding and membrane 
fusion indicate that vaccines based on the S protein could induce antibodies to block 
virus binding and virus entry through fusion inhibition. Antibodies with such properties 
are well known for their capacity to neutralize virus infections. Thus, among all 
structural proteins of coronaviruses, the S glycoprotein is considered the main 
antigenic component that is responsible for inducing host immune responses, 
neutralizing antibodies and/or protective immunity against virus infection (Du et al., 
2009). S proteins have therefore been selected as preferred targets for the 
development of new coronavirus-specific vaccines and anti-virals. 
Several vaccines that are based on the full-length S protein of SARS-CoV have been 
reported. Yang et al. showed that a DNA vaccine encoding the full-length S protein of 
the SARS-CoV Urbani strain induced both T-cell and neutralizing-antibody responses, 
as well as protective immunity in a mouse model (Yang et al., 2004). Other groups 
have also shown that vaccination of mice or monkeys with highly attenuated modified 
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vaccinia virus Ankara (MVA) which encodes the full-length S protein of the SARS-CoV 
Urbani or HKU39849 strain elicited S-specific neutralizing antibodies and protective 
immunity as evidenced by decreased virus loads in the respiratory tracts of animals 
after challenge infections with homologous SARS-CoV (Bisht et al., 2004; Chen et al., 
2005). 
These reports suggest that the full-length S protein is highly immunogenic and induces 
protection against SARS-CoV challenge and that neutralizing antibodies alone may be 
able to suppress virus proliferation. Moreover, these data further supported the 
rationale that efficacious coronavirus-specific vaccines can be developed based on the 
S protein as the only antigen.  
Coronavirus spike protein can be expressed in a native state by MVA vectors. 
The spike protein of coronavirus is a type I transmembrane protein and highly 
glycosylated. Spike proteins assemble into trimers on the virion surface to form the 
distinctive “corona” or crown-like appearance. The ectodomain of all coronavirus spike 
proteins share the same organization in two domains: An N-terminal domain named 
S1 that is responsible for receptor binding and a C-terminal S2 domain responsible for 
fusion (Belouzard et al., 2012).  
The secretory pathway of the cell has an important quality control function and the 
trafficking of a protein from the endoplasmic reticulum to the plasma membrane is a 
sign of proper secondary modification and folding. The N-linked oligosaccharide 
pathway is frequently used for tracking protein movement. Addition of N-linked 
oligosaccharides occurs in the endoplasmic reticulum and the conversion of the high 
mannose form to complex endo H-resistant N-linked chains occurs on transport from 
the cis to the medial Golgi compartment (Figure 8).  
DISCUSSION  39 
 
Figure 8 The life cycle of MERS-CoV                                                                       
(from Lu et al., 2013, with permission) 
 
We specifically detected a protein with an estimated molecular mass of about 200 kDa 
in lysates from MVA-MERS-S- and MVA-MERS-SHA-infected Vero cells by using sera 
from MERSCoV-infected macaques in Western blot analysis. Furthermore, the use of 
the monoclonal anti-HA tag antibody confirmed the production of a protein doublet of 
200 to 210 kDa in cells infected with MVA-MERSSHA. The molecular masses of the 
200- to 210-kDa polypeptides detected by SDS-PAGE were significantly higher than 
the 149 kDa predicted for MERS-CoV S protein based on its nucleotide sequence. 
The treatment of lysates with glycosidase specific for N-linked carbohydrates reduced 
the 210-kDa protein doublet to a sharp protein band of about 150 kDa a value closely 
matching the predicted mass of unmodified MERS-CoV S protein. A subpopulation of 
S protein molecules which was resistant to endo H indicated that the S protein was 
successfully trafficked to medial Golgi apparatus. Furthermore, the detection of two 
bands was consistent with cleavage of the S protein (200 kDa) into an N-terminal 
(80kDa) and a C-terminal (not detected) indicated that S protein could be cleaved into 
functional S1 and S2 subunits. In this context, Gierer et al found the serine 
transmembrane protease TMPRRS2 to activate the fusion between viral and host cell 
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membrane by cleaving the S protein into S1 and S2 subunits. Importantly, MERS-CoV 
S protein mediated fusion was also revealed using immunostaining of MVA vector 
infected cell cultures with anti-HA tag monoclonal or polyclonal antibodies from MERS-
CoV-infected macaques (Figure 9). These results suggested synthesis of functional 
recombinant MERS-CoV SHA and S proteins in MVA vector infected avian and 
mammalian cells. 
 
Figure 9 Fusion of  MVA-MERS-S infected Vero cells 
 
MVA-MERS-S is safe and replication deficient vector virus. 
The growth kinetics of MERS-CoV on CEF cells showed that the recombinant viruses 
were able to replicate in CEF cells to high titers (108 PFU/ml) and can be readily 
amplified at larger scale. Importantly, the MVA-MERS-S recombinant viruses were 
unable to productively grow in defined human cell cultures (cell lines HeLa and 
HaCaT). This data confirmed the maintenance of replication-deficiency and biological 
safety of the MVA vector virus. Moreover, this conclusion from in vitro experiments is 
well supported by preliminary data from vaccination experiments in mouse models. 
The MVA-MERS-S vaccine was well tolerated in all vaccinated animals with no 
adverse reactions being observed. Overall, these results from the preclinical 
characterization of the recombinant viruses strongly supported the usefulness of MVA-
MERS-S for further development as candidate vaccine for humans and animals. 
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MVA-MERS-Sinduces MERS-CoV neutralizing antibody responses. 
First immunizations of mice with MVA-MERS-S demonstrated the induction of high 
levels of neutralizing antibodies. The IC50 for MERS-CoV neutralization reached 
almost 2000after two applications of MVA-MERS-S vaccine. This high titer of 
neutralizing antibodies also supported that the MVA vector produces an authentic and 
immunogenic MERS-CoV S protein for in vivo antigen presentation and immune 
recognition. In addition, the prime/boost vaccination protocol may have also 
contributed to the increased production of neutralizing antibodies. It was reported that 
MVA-based booster immunizations can modulate the elicited antigen-specific immune 
response towards a mixed Th1/Th2 response pattern and contribute to optimize the 
cell mediated responses (Schulze et al., 2008). Moreover, homologous prime/boost 
immunizations with an MVA candidate vector vaccine against tuberculosis showed 
that highly persistent and protective immune responses can be elicited for at least 16 
months after the initial vaccination (Kolibab et al., 2010). 
Sequence and modeling analysis using data from several human coronaviruses 
allowed to reveal the potential receptor-binding domain of MERS-CoV in the S 
glycoprotein (Jiang et al., 2013; Raj et al., 2013). The MERS-CoV-neutralizing activity 
of sera from MVA-MERS-S vaccinated mice could be partly blocked by preincubation 
with recombinant proteins that encompass the MERS-S receptor binding domain. This 
observation confirmed the proposed site of the receptor binding domain in the MERS-
S protein and also indicated the other parts of the S protein might be targets of MERS-
CoV neutralizing antibodies.  
Chan et al. have reported that sera collected from convalescent SARS patients might 
contain cross-reactive antibodies to MERS-CoV as detected by both 
immunofluorescent and neutralizing antibody tests (Chan et al., 2013c). In response to 
this observation, the specificity of the antibody response induced by MVA-MERS-S 
was confirmed by the absence of any detectable neutralization of the SARS 
coronavirus (SARS-CoV). Also another study showed that monoclonal antibodies 
specific for the receptor binding domain of the SARS-CoV S protein exhibited no 
cross-reactive or cross-neutralizing activity to MERS-CoV. This data suggests that the 
receptor binding domains of S proteins from SARS-CoV and MERS-CoV may not 
contain significant epitopes for inducing cross-reactive antibody responses (Du et al., 
2013b). 
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Future directions in developing an MVA-MERS-S vaccine. 
The initial immunogenicity testing of the MVA-MERS-S vaccine in the mouse model 
demonstrated its ability to induce MERS-CoV specific antibodies. However, additional 
studies will be needed for further development as realistic candidatevaccine against 
MERS-CoV infections. In addition to neutralizing antibodies, Xu et al. reported that 
SARS-CoV-specific cytotoxic T lymphocyte responses were detected in patients 
following recovery from SARS (Xu and Gao, 2004). In conclusion, it was suggested 
that both humoral and cellular immune responses are important for clearance of 
SARS-CoV and survival of infection. Thus, as SARS-CoV is considered to be a close 
relative of MERS-CoV the requirement for inducing a strong T cell response may be 
also important for an efficacious MERS-CoV vaccine. It is encouraging that in previous 
studies the SARS-CoV S protein proved to be a suitable antigen for induction of strong 
T cell responses (Czub et al., 2005. Du et al., 2008) . Moreover, the MVA vector 
platform has been repeatedly shown to be highly suitable for the development of 
vaccines that induce T cell immunity against various infectious agents and cancer 
associated antigens (Drexler et al. 2004). Therefore, the future analysis of MERS-CoV 
specific cytotoxic T lymphocytes may reveal additional advantageous properties of this 
MVA vaccine candidate.  
In MERS patients, MERS-CoV infection was reported to cause severe pneumonia with 
the replication of MERS-CoV being largely restricted to the lower respiratory tract. 
Thus, for optimized protection of lung tissue against infection and pathology it should 
be essential to stimulate robust mucosal immune responses to MERS-CoV. Therefore, 
further work must aim at the comparative evaluation of different vaccination protocols 
for capacity to elicit humoral and cellular immune responses at systemic and mucosal 
levels.  
Furthermore, preclinical testing must include the assessment of the protective capacity 
of MVA-MERS-S immunization in animal models of MERS-CoV infection. However, it 
was reported that MERS-CoV cannot replicate in commonly used laboratory animals 
hampering the development of convenient infection models (de Wit et al., 2013; 
Coleman et al. 2014). DPP4 was identified as the surface receptor employed by the 
MERS coronavirus to gain entry into host cells including those of human origin. 
Interestingly, although mouse DPP4 is highly similar (92% identity) to the human 
DPP4, mouse DPP4 does not serve as a functional receptor for MERS-CoV infection 
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(Cockrell et al., 2014). Therefore, MERS-CoV fails to productively infect normal or 
immunodeficient mice including BALB/c, C57B/6, 129SvEv, or STAT1 knockout mice 
on the 129SvEv background. Recently, Zhao and coworkers described a novel 
approach to developing a mouse model for MERS-CoV infection. The transduction of 
mice with recombinant adenovirus allowed for the in vivo expression of the human 
DPP4 receptor, and, most excitingly, upon MERS-CoV infection these mice developed 
interstitial pneumonia (Zhao et al., 2014). This model provides encouragement for the 
development of transgenic mouse model with human DPP4 receptor. 
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VI.  SUMMARY 
About 10 years after the outbreak of SARS, Middle East respiratory syndrome 
coronavirus (MERS-CoV), a novel human coronavirus that caused outbreaks of a 
SARS-like illness in the Middle East, is now considered a threat to global public health. 
Since the first report, WHO had been informed of 189 laboratory-confirmed cases of 
infection with MERS-CoV including 82 deaths (a case fatality rate >40%). 
In this study, we generated a MERS vaccine candidate by using the live attenuated 
modified vaccinia virus Ankara (MVA) as a vector. The full-length MERS-CoV spike 
(S) glycoprotein gene was introduced into the MVA genome (MVA-S). A second 
version containing a c-terminal epitope tag (influenza hemagglutinin; MVA-SHA) was 
generated using the same technology. Growth kinetics of MVA and MVA-S in CEF, 
HeLa, and HaCaT cells showed that the newly generated recombinant MVA-S is 
replication incompetent in mammalian cells. Cells infected with MVA-S or MVA-SHA 
synthesized a 200-kDa protein which was recognized by sera from MERS-CoV-
infected macaques. Further immunoblot analysis of MVA-SHA infected cells 
demonstrated a second protein of about 85 kDa. Further studies indicated that S was 
N-glycosylated and migrated in SDS polyacrylamide gels with an apparent mass of 
approximately 150 kDa and 55 kDa after treatment with peptide N-glycosidase F. The 
acquisition of resistance to endoglycosidase H indicated trafficking of S to the medial 
Golgi compartment. 
Intramuscular inoculations of BALB/c mice with MVA-MERS-S produced high levels of 
serum antibodies neutralizing MERS-CoV. The specificity of the induced MVA-MERS-
S antibodies for MERS-CoV was confirmed by the absence of detectable 
neutralization against SARS coronavirus (SARS-CoV). In addition, the MERS-CoV-
neutralizing activity of these serum samples could be only partly blocked by 
preincubation with proteins that encompass the receptor binding domain of the S 
protein. 
Overall, these results support the further development of MVA-MERS-S as candidate 
emergency vaccine against MERS-CoV. 
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VII.  ZUSAMMENFASSUNG 
Ein Jahrzehnt nach der SARS (severe acute respiratory syndrome)-Pandemie 
alarmiert ein neues humanes Coronavirus, das Middle East Respiratory Syndrom 
Coronavirus (MERS-CoV), die Gesundheitsbehörden. Die durch schwere 
respiratorische Symptomatik charakterisierte Krankheit wurde bisher in 189 Fällen von 
der WHO bestätigt. Bei 82 Patienten endete die Infektion tödlich.  
Im Rahmen dieser Arbeit wurde ein möglicher Impfstoff gegen das MERS-CoV 
entwickelt, der auf dem Modifizierten Vaccinia virus Ankara (MVA) als Vektor basiert. 
Hierzu wurde das Gen für das Spike (S)-Protein des MERS-CoV in eine 
Deletionsstelle des MVA-Genoms inseriert (MVA-S). In einer zweiten Variante wurde 
das Spike-Protein um eine Tag-Sequence (Epitop des Influenzavirus-Hämagglutinin) 
ergänzt (MVA-SHA). MVA-S oder MVA-SHA infizierte Zellen synthetisierten ein ca. 
200 kDa großes Protein, das im Immunoblot spezifisch mit Serum eines MERS-CoV-
infizierten Makakenaffen reagierte. Weitere Untersuchungen mit dem MVA-SHA 
zeigten ein zweites Protein von ca. 85 kDa Größe. Durch Behandlung mit Petide N-
Glycosidase F reduzierte sich die Masse der nachgewiesenen Proteine auf ca. 150 
und 55 kDA und bestätigte die Glykosilierung des S-Proteins. Die nachgewiesene 
Resistenz des Glycoproteins gegenüber der Endoglycosidase H deutet auf die 
Passage des Trans-Golgi-Netzwerkes hin. Die rekombinanten Viren MVA-S und MVA-
SHA vermehren sich in Hühnerembryofibroblasten nicht aber in humanen Zellen. Ein 
Befund der die biologische Sicherheit der rekombinanten MVA unterstreicht.  
BALB/c Mäuse bildeten nach intramuskulärer Injektion mit MVA-S hohe Titer MERS-
CoV neutralisierender Antikörper. SARSCoV wurde hingegen nicht neutralisiert. Die 
Präinkubation der Seren mit der Rezeptor-bindenden-Domäne des S-Proteins führte 
zur Reduktion der MERS-CoV-neutralisierenden Wirkung. Diese Ergebnisse 
bestätigten die Bedeutung der Rezeptor-bindenden-Domäne als Antigenstruktur und 
sprechen gleichzeitig für das Vorhandensein anderer Epitope für MERS-CoV 
neutralisierende Antikörper. 
Das hier generierte und untersuchte rekombinante Virus MVA-MERS-S ist daher ein 
vielversprechender Impfstoffkandidat, der für weitere präklinische und klinische 
Untersuchungen zur Verfügung steht. 
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IX.  ABBREVIATIONS 
ACE   Angiotensin-converting enzyme 2 
ADA   Adenosine deaminase 
AIDS   Acquired immune deficiency syndrome 
ARDS   Acute respiratory distress syndrome 
cDNA   complementary DNA 
CEF    Chicken embryo fibroblast cells 
CPE    Cytopathic effect 
CVA   Chorioallantois vaccinia virus Ankara 
DC   Dentritic cell 
DNA   Desoxyribonucleic acid 
DPP4    Dipeptidyl peptidase-4 
E   Envelope 
ELISA   Enzyme-linked immunosorbent assay 
EMC   Erasmus Medical Centre 
Endo H  Endoglycosidase H 
HA    Hemagglutinin 
HIV    Human immunodeficiency virus 
ICTV   International Committee on Taxonomy of Viruses 
IFN    Interferon 
IFA    Indirect fluorescent assay 
Ig   Immunoglobulin 
kb   Kilobase 
kDa   Kilodalton 
KSA   Kingdom of Saudi Arabia 
M   Membrane 
MERS   Middle East respiratory syndrome 
MERS-CoV   Middle East respiratory syndrome coronavirus 
ml   Milliliter 
MOI    Multiplicity of infection 
mRNA  messenger ribonucleic acid  
MVA    Modified vaccinia virus Ankara 
N   Nucleocapsid 
ORF   Open reading frame 
PAGE   Polyacrylamide gel electrophoresis 
PBS   phosphate buffered saline 
PCR   Polymerase chain reaction 
PFU   Plaque forming unit 
PNGase F  Peptide-N-glycosidase F 
RBD   Receptor binding domain 
S   Spike protein 
SARS   Severe acute respiratory syndrome 
SARS-CoV  Severe acute respiratory syndrome coronavirus 
SDS   Sodium dodecyl sulfate 
TMPRRSS2  Type II transmembrane serine proteases 
TNF   Tumor necrosis factor 
UAE   United Arab Emirates 
UK   United Kingdom 
VACV   Vaccinia virus 
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